Fasting Insulin and HOMA-IR: The Early Warning Your Sugar Test Misses

Most people's first sign of a blood-sugar problem is a fasting glucose or HbA1c that finally drifts out of range. By then, though, the underlying process has often been running quietly for years. Fasting insulin — and the simple score built from it, HOMA-IR — is the test that can catch that process earlier, while there's still the most to gain from acting. It's also one of the more misunderstood numbers, so this is a plain-language, current guide to what it measures, what it doesn't, and where it fits. It's general education, not a diagnosis; your own results are read by a doctor who knows your history.

What is insulin resistance, and what is HOMA-IR?

Insulin is the hormone that lets your cells take up glucose from the blood. Insulin resistance means your cells have become less responsive to it — so your pancreas compensates by pumping out more insulin to get the same job done. For a long time this works: blood sugar stays normal precisely because insulin is running high behind the scenes.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a way to estimate that hidden effort from a single fasting blood draw. It combines your fasting glucose and fasting insulin into one number — roughly, glucose multiplied by insulin, divided by a constant ². A higher HOMA-IR means the pancreas is working harder to hold the line, which is the signature of insulin resistance.

The early-warning idea

Here's why it matters. Because insulin rises first to keep glucose normal, a high fasting insulin and HOMA-IR can appear well before fasting glucose or HbA1c ever look abnormal — by an estimated decade or more in long-term studies ¹. The standard sugar tests, in other words, tend to catch the problem late, once the pancreas can no longer fully compensate. HOMA-IR can flag it during the window when lifestyle change does the most good.

Why it isn't a routine diagnostic

If it's such an early warning, why isn't fasting insulin on every panel? Because of a real technical limitation: insulin assays are not standardised between laboratories. The same blood sample can give different insulin values on different analysers, so there is no single universal cutoff for HOMA-IR ². That's why the major diabetes bodies still screen with fasting glucose and HbA1c, not insulin, and why HOMA-IR is used mainly for risk-stratification and research rather than diagnosis.

In practice, studies use adult HOMA-IR cutoffs clustering around 2.0–3.0. One detail matters a lot in this part of the world: Asian populations tend to develop insulin resistance at lower values and lower body weights, with cutoffs often set around 1.4–2.5 ². A "normal-looking" BMI doesn't rule it out. Insulin resistance is also far from rare — a 2025 global review estimated it affects roughly a quarter of adults ³.

There's also a cheaper cousin worth knowing about: the TyG index, calculated from fasting triglycerides and glucose (both already on a standard panel), which has gained ground since 2022 as a practical surrogate for insulin resistance without needing an insulin assay at all ⁴.

What insulin resistance connects to

Insulin resistance sits upstream of a cluster of common problems, which is why the number is interesting beyond diabetes risk. It's central to metabolic syndrome — the combination of abdominal weight, raised blood pressure, blood-sugar and lipid changes that together raise heart-disease risk ⁵. It's the main driver of fatty liver disease (now often called MASLD), where a raised HOMA-IR tracks with the liver changes. And it's a core feature of PCOS in women, where insulin resistance runs markedly higher than average ². Seen this way, HOMA-IR is less a single-disease test and more a window onto whole-body metabolic health.

The hopeful part: it's reversible

The reason to look early is that insulin resistance responds to change. Modest weight loss and regular exercise measurably lower HOMA-IR, and losing even 5–7% of body weight substantially cuts the risk of progressing to type-2 diabetes ¹. Newer GLP-1-class medications also improve insulin resistance, partly through weight loss — but lifestyle remains the foundation, and it's effective. That's the whole argument for catching the problem during the silent, compensating phase rather than after the sugar numbers have finally moved.

What we see at the clinic

A fair number of the people we meet in Pattaya are metabolically "in-between": normal fasting glucose, a borderline or still-normal HbA1c, but expanding waistlines, a fatty-liver note on an ultrasound, or a strong family history of diabetes — often at a body weight that doesn't look high. That's exactly the group where insulin resistance can be well underway while the standard sugar tests still read fine, and where it's especially relevant given how readily Asian metabolisms cross into risk at lower numbers. We use fasting insulin and HOMA-IR as a refinement — one more lens, read alongside glucose, HbA1c and lipids — not as a diagnosis, and we're upfront that the assay isn't perfectly standardised. What it changes is the conversation: it can turn a vague "you're probably fine for now" into a concrete, early reason to act while the process is still very reversible.

Common questions

My glucose and HbA1c are normal — can I still have insulin resistance? Yes, and that's the main reason to consider this test. Insulin rises first to keep glucose normal, so resistance can be present — sometimes for years — while the standard sugar tests still read fine ¹.

Is a high HOMA-IR a diagnosis of diabetes or prediabetes? No. It estimates insulin resistance, a risk state, not a disease — and because insulin assays aren't standardised there's no universal cutoff ². It refines your risk picture; diagnosis still rests on glucose and HbA1c.

Why would my cutoff be different from someone else's? Partly because labs use different insulin assays, and partly because thresholds differ by population — Asian and South Asian people tend to develop insulin resistance at lower HOMA-IR values and lower body weight ². It's read in context, not against one universal line.

Can I improve it? Genuinely, yes. Modest weight loss and regular activity lower HOMA-IR, and losing 5–7% of body weight meaningfully reduces the risk of developing type-2 diabetes ¹. That reversibility is the reason to find it early.

Do I need the insulin test, or is the TyG index enough? For many people the TyG index — from triglycerides and glucose already on a routine panel — is a reasonable, cheaper surrogate that avoids the insulin-assay problem ⁴. Which to use is a conversation with your doctor.

Key takeaway

Fasting insulin and HOMA-IR estimate insulin resistance — how hard your body is working to keep blood sugar normal — and their value is timing: insulin climbs years before glucose or HbA1c ever look abnormal, so this can catch a metabolic problem early ¹. It isn't a standardised diagnostic — assays vary, cutoffs differ, and Asian populations cross into risk at lower values — so treat it as a risk refinement, read with the rest of your panel, not a verdict ². The reason it's worth the early look is the best part: insulin resistance is reversible, and modest weight loss and exercise move the number ¹. If your sugar tests are "fine" but your waist, liver or family history say otherwise, it's a worthwhile line to discuss as part of a baseline.